Literature DB >> 14500375

Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma.

Benno Küsters1, Robert M W de Waal, Pieter Wesseling, Kiek Verrijp, Cathy Maass, Arend Heerschap, Jelle O Barentsz, Fred Sweep, Dirk J Ruiter, William P J Leenders.   

Abstract

We reported previously that vascular endothelial growth factor isoform A (VEGF-A) expression by Mel57 human melanoma cells led to tumor progression in a murine brain metastasis model in an angiogenesis-independent fashion by dilation of co-opted, pre-existing vessels and concomitant enhanced blood supply (B. Kusters et al., Cancer Res., 62: 341-345, 2002). Here, we compare the activities of the 121, 165, and 189 VEGF-A isoforms in this model by transfecting Mel57 cells with the respective cDNAs and by injecting the resulting stably transfected cell lines in the internal carotid arteries of nude mice (n = 10 for each isoform). Although the three isoforms had similar potency to induce endothelial cell proliferation, VEGF(121) expression did not result in sprouting angiogenesis but rather led to extensive vasodilation and increased permeability of pre-existing, predominantly peritumoral vessels. Sometimes, proliferating endothelial cells accumulated in vessel lumina, giving these a microvascular, glomeruloid, proliferation-like appearance. Expression of VEGF(165) or VEGF(189) was associated with induction of an intratumoral neovascular bed. In VEGF(165)-expressing tumors, daughter endothelial cells were distributed among newly formed vessels that were extensively dilated. This also occurred in VEGF(189) tumors, but there, vasodilation was less pronounced. Using contrast-enhanced magnetic resonance imaging, the different vascular phenotypes were visualized on characteristic radiological images. VEGF(165) expression was the most unfavorable of the three. Mice carrying VEGF(165) tumors became moribund earlier than those carrying VEGF(121)-expressing tumors (16 +/- 4 days versus 22 +/- 3 days). Our data demonstrate that VEGF-A isoforms differ in angiogenic properties that can be visualized by contrast-enhanced magnetic resonance imaging.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500375

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Phase contrast MRI is an early marker of micrometastatic breast cancer development in the rat brain.

Authors:  Matthew D Budde; Eric Gold; E Kay Jordan; Melissa Smith-Brown; Joseph A Frank
Journal:  NMR Biomed       Date:  2011-09-22       Impact factor: 4.044

2.  Matrix-Bound VEGF Mimetic Peptides: Design and Endothelial Cell Activation in Collagen Scaffolds.

Authors:  Tania R Chan; Patrick J Stahl; S Michael Yu
Journal:  Adv Funct Mater       Date:  2011-11-22       Impact factor: 18.808

Review 3.  Current approaches to the treatment of metastatic brain tumours.

Authors:  Taofeek K Owonikoko; Jack Arbiser; Amelia Zelnak; Hui-Kuo G Shu; Hyunsuk Shim; Adam M Robin; Steven N Kalkanis; Timothy G Whitsett; Bodour Salhia; Nhan L Tran; Timothy Ryken; Michael K Moore; Kathleen M Egan; Jeffrey J Olson
Journal:  Nat Rev Clin Oncol       Date:  2014-02-25       Impact factor: 66.675

Review 4.  Embracing rejection: Immunologic trends in brain metastasis.

Authors:  S Harrison Farber; Vadim Tsvankin; Jessica L Narloch; Grace J Kim; April K S Salama; Gordana Vlahovic; Kimberly L Blackwell; John P Kirkpatrick; Peter E Fecci
Journal:  Oncoimmunology       Date:  2016-04-11       Impact factor: 8.110

Review 5.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors:  Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal:  Cytokine Growth Factor Rev       Date:  2013-11-27       Impact factor: 7.638

Review 6.  Brain metastases: epidemiology and pathophysiology.

Authors:  Igor T Gavrilovic; Jerome B Posner
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 7.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

8.  Age-related macular degeneration: current treatments.

Authors:  Jean Pierre Hubschman; Shantan Reddy; Steven D Schwartz
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  Epo is relevant neither for microvascular formation nor for the new formation and maintenance of mice skeletal muscle fibres in both normoxia and hypoxia.

Authors:  Luciana Hagström; Onnik Agbulut; Raja El-Hasnaoui-Saadani; Dominique Marchant; Fabrice Favret; Jean-Paul Richalet; Michèle Beaudry; Thierry Launay
Journal:  J Biomed Biotechnol       Date:  2010-04-14

10.  3D multi-cell simulation of tumor growth and angiogenesis.

Authors:  Abbas Shirinifard; J Scott Gens; Benjamin L Zaitlen; Nikodem J Popławski; Maciej Swat; James A Glazier
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.